Massachusetts General Hospital Cancer Center

https://www.massgeneral.org/cancer-center

 

GRACE
Avatar

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Resistance? How to Assess for Osimertinib Resistance?

By GRACE FEATURING Zofia Piotrowska
By GRACE FEATURING Zofia Piotrowska
103 views
March 1, 2021
0 Comments
Login to view comments. Click here to Login
Videos
11:21
Massachusetts General Hospital Cancer Center

Uveal Melanoma for Community Oncologists

Feat. K. Montazeri
14:06
Insights from 2023 Society for Melanoma Research Annual Meeting

2023 SMR Congress Insights: "Time-to-Event Machine Learning Pre…

Feat. Y. Semenov
18:31
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CAR/BsAb Toxicity in MM - Prevention, Treatment, and Surv…

Feat. N. S. Raje
10:42
Insights from 2023 EHA® Annual Meeting

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

Feat. A. Fathi
06:25
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 1/2 TRIDENT-1 Trial - Intracranial …

Feat. J. Lin
16:49
Massachusetts General Hospital Cancer Center

ESR1 Mutations in HR+/HER2- mBC and Their Role in Treatment Outcomes

Feat. S. Wander
17:54
Massachusetts General Hospital Cancer Center

Genetic Heterogeneity in Brain Metastases and Implications for Clini…

Feat. P. Brastianos
09:52
Massachusetts General Hospital Cancer Center

Maintenance Therapy in AML: Protecting Remission, Extending Survival…

Feat. A. Brunner
08:20
Massachusetts General Hospital Cancer Center

ESMO 2021 Updates on 1L DKN-01 + Tislelizumab & Chemotherapy in …

Feat. S. Klempner
12:08
Massachusetts General Hospital Cancer Center

Selpercatinib Efficacy & Safety in Patients With RET-Altered Thy…

Feat. L. Wirth
10:05
i3 Health

Emerging Treatment Strategies for Advanced Cholangiocarcinoma: Molec…

Feat. L. Goyal
50:37
Massachusetts General Hospital Cancer Center

Next Steps in FGFRi in Cholangiocarcinoma: FGFR Pathway & Curren…

Feat. L. Goyal
04:27
Massachusetts General Hospital Cancer Center

ASCO 2021 Highlights From GEOMETRY mono-1 Study on Advanced NSCLC: C…

Feat. R. Heist
16:46
Virtual West Oncology Conference

2021 Updates on mTNBC: Do Olaparib/Talazoparib Improve PFS Compared …

Feat. N. Vidula
18:15
CancerGRACE

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …

Feat. Z. Piotrowska
10:33
GRACE

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…

Feat. Z. Piotrowska
31:44
Massachusetts General Hospital Cancer Center

Tumor Infiltrating Lymphocytes: What Is the Data That Supports the P…

Feat. K. Flaherty
13:52
2020 ASCO Virtual Direct™ Highlights

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dx…

Feat. I. Dagogo-Jack
05:44
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

Feat. I. Dagogo-Jack
07:33
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Sug…

Feat. I. Dagogo-Jack
07:14
ecancer

2020 ESMO Update on ADCs in mTNBC: Is Sacituzumab Govitecan More Ben…

Feat. A. Bardia
13:34
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

Feat. I. Dagogo-Jack
26:39
Virtual Diversity in Cancer Care

Risk Factors in Lung Cancer: Which Risk Factor Is Predominant? How I…

Feat. I. Dagogo-Jack